Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
News|Articles|December 1, 2025
Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management
Fact checked by: Victoria Johnson, Patrick Campbell
Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.
Advertisement
Advertisement
Over the past several years,
Related to this article
However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
Advertisement
Advertisement